Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 05, 2020

SELL
$127.12 - $172.34 $1.45 Million - $1.96 Million
-11,400 Closed
0 $0
Q2 2020

Aug 10, 2020

BUY
$93.0 - $171.7 $452,724 - $835,835
4,868 Added 74.53%
11,400 $1.83 Million
Q1 2020

May 11, 2020

BUY
$82.38 - $131.64 $538,106 - $859,872
6,532 New
6,532 $639,000
Q1 2019

May 13, 2019

SELL
$106.67 - $151.68 $997,364 - $1.42 Million
-9,350 Closed
0 $0
Q4 2018

Feb 08, 2019

BUY
$97.32 - $148.76 $197,559 - $301,982
2,030 Added 27.73%
9,350 $1.02 Million
Q3 2018

Nov 05, 2018

SELL
$115.31 - $161.51 $163,740 - $229,344
-1,420 Reduced 16.25%
7,320 $1.18 Million
Q2 2018

Aug 13, 2018

SELL
$71.74 - $153.69 $1.63 Million - $3.5 Million
-22,780 Reduced 72.27%
8,740 $1.16 Million
Q1 2018

May 15, 2018

BUY
$54.02 - $82.27 $605,834 - $922,658
11,215 Added 55.23%
31,520 $2.34 Million
Q4 2017

Feb 07, 2018

BUY
$47.64 - $56.75 $432,809 - $515,573
9,085 Added 80.97%
20,305 $1.13 Million
Q3 2017

Nov 13, 2017

BUY
$35.73 - $47.15 $400,890 - $529,023
11,220
11,220 $509,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.7B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Lisanti Capital Growth, LLC Portfolio

Follow Lisanti Capital Growth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lisanti Capital Growth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lisanti Capital Growth, LLC with notifications on news.